IRadimed Corporation (IRMD) AI Stock Analysis

IRADIMED CORPORATION specializes in the development, manufacturing, marketing, and global distribution of medical devices compatible with magnetic resonance imaging (MRI) technology. Its product portfolio features the MRidium MRI-compatible intravenous (IV) infusion pump system with disposable IV tubing sets, alongside MRI-compatible patient vital signs monitoring systems. The company also supplies non-magnetic IV poles, wireless remote displays and controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors and accessories. Serving hospitals, acute care facilities, and outpatient imaging centers, IRADIMED distributes products through direct sales personnel, regional sales directors, clinical support teams, and independent distributor partnerships.

From FY2021 to FY2025, IRadimed expanded annual revenue from $41.8M to $83.8M, reflecting a 5-year revenue CAGR of 21.5% from FY2020 to FY2025. Net income increased from $9.3M in FY2021 to $22.5M in FY2025, with EPS climbing from $0.83 to $1.92. Over this timeframe, operating margin widened from 23.5% in FY2021 to 31.2% in FY2025, while gross margin remained steady at 76.7% in FY2025. For the trailing twelve months, revenue reached $86.3M. However, in the latest quarter ending June 30, 2026, quarterly revenue growth slowed to 0.3% year-over-year, and quarterly earnings fell 9.3%.

As of June 30, 2026, IRadimed held $59.1M in cash and short-term investments, with total assets of $115.0M and shareholders' equity of $101.7M. The company maintains strong liquidity, evidenced by a current ratio of 9.46. In FY2025, it generated $24.9M in operating cash flow and $17.2M in free cash flow. Capital allocation in FY2025 included $7.8M for capital expenditures and $15.0M in dividends paid, while the 5-year share count change was 1.9%.

IRadimed trades at a trailing P/E of 49.3x and a forward P/E of 41.2x, substantially above the median of its US-listed Healthcare peers at 24.6x and 17.3x, respectively. Its enterprise value of $1.05B reflects an EV/EBITDA multiple of 36.1x, compared to the peer median of 12.0x, while its price-to-sales ratio is 13.1x against the peer median of 4.1x. Over the past year, the stock returned 17.7%, slightly exceeding the 16.8% return for the S&P 500. Over five years, IRadimed gained 165.1% compared to 83.0% for the S&P 500.

IRadimed pays a quarterly dividend with a forward annual rate of $0.80, providing a dividend yield of 0.91%. The company's payout ratio stands at 57.6%, and it has paid dividends for 5 consecutive years. Its most recent ex-dividend date was August 14, 2026.

Wall Street analysts cover IRadimed with 2 Strong Buy ratings, 0 Buy ratings, and 1 Hold rating. The mean price target is $118.00, representing a 33.7% premium over the last close of $88.27. For the fiscal year ending December 31, 2026, analysts estimate EPS of $2.11 on revenue of $92.1M. IRadimed beat EPS estimates in 3 of the last 4 quarters, and its next earnings release is scheduled for November 2, 2026.

This page is an AI-written research summary of IRadimed Corporation (IRMD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: IRMD income statement, IRMD balance sheet, IRMD key metrics, IRMD analyst forecast, IRMD chart. See the IRMD stock overview for the latest quote and news.